Active motif finder-a bio-tool based on mutational structures in DNA sequences

Active Motif Finder （AMF） is a novel algorithmic tool, designed based on mutations in DNA sequences. Tools available at present for finding motifs are based on matching a given motif in the query sequence. AMF describes a new algorithm that identifies the occurrences of patterns which possess all kinds of mutations like insertion, deletion and mismatch. The algorithm is mainly based on the Alignment Score Matrix （ASM） computation by com paring input motif with full length sequence. Much of the effort in bioinformatics is directed to identify these motifs in the sequences of newly discovered genes. The proposed bio-tool serves as an open resource for analysis and useful for studying polymorphisms in DNA sequences. AMF can be searched via a user-friendly interface. This tool is intended to serve the scientific community working in the areas of chemical and structural biology, and is freely available to all users, at http：//www.sastra.edu/scbt/amf/.

Simulation of optimal dose regimens of photoactivated curcumin for antimicrobial resistance pneumonia in COVID-19 patients:A modeling approach

Background:Secondary antimicrobial resistance bacterial(AMR)pneumonia could lead to an increase in mortality in COVID-19 patients,particularly of geriatric patients with underlying diseases.The comedication of current medicines for AMR pneumonia with corticosteroids may lead to suboptimal treatment or toxicities due to drug-drug interactions(DDIs).Objective:This study aimed to propose new promising dosage regimens of photoactivated curcumin when co-administered with corticosteroids for the treatment of antimicrobial resistance(AMR)pneumonia in COVID-19 patients.Methods:A whole-body physiologically-based pharmacokinetic(PBPK)with the simplified lung compartments model was built and verified following standard model verification(absolute average-folding error or AAFEs).The pharmacokinetic properties of photo-activated were assumed to be similar to curcumin due to minor changes in physiochemical properties of compound by photoactivation.The acceptable AAFEs values were within 2-fold.The verified model was used to simulate new regimens for different formulations of photoactivated curcumin.Results:The AAFEs was 1.12-fold.Original formulation(120 mg once-daily dose)or new intramuscular nano-formulation(100 mg with a release rate of 10/h given every 7 days)is suitable for outpatients with MRSA pneumonia to improve patient adherence.New intravenous formulation(2000 mg twice-daily doses)is for hospitalized patients with both MRSA and VRSA pneumonia.Conclusion:The PBPK models,in conjunction with MIC and applied physiological changes in COVID-19 patients,is a potential tool to predict optimal dosage regimens of photo-activated curcumin for the treatment of co-infected AMR pneumonia in COVID-19 patients.Each formulation is appropriate for different patient conditions and pathogens.